Get tips and insights from health-care professionals and people with diabetes, share your thoughts, and ask questions on our blog.
- Alternative Medicine/ Complementary Therapies
- Blood Glucose Monitoring
- Dental Health
- Diabetes News
- Diabetes Research
- Diabetic Complications
- Diagnosis
- Emotional Health
- Exercise
- Eyes & Vision
- Foot Care
- General Diabetes & Health Issues
- Heart Health
- High Blood Glucose
- Insulin & Other Injected Drugs
- Kids & Diabetes
- Living With Diabetes
- Low Blood Glucose
- Men's Health
- Money Matters
- Nutrition & Meal Planning
- Oral Medicines
- Sexual Health
- Tools & Technology
- Traveling With Diabetes
- Type 1 Diabetes
- Type 2 Diabetes
- Weight Loss
- What We're Reading
- Women's Health
Sign up for our weekly e-mail newsletter and receive a FREE GIFT! Enter your e-mail below.
Links to help you learn more about diabetes.
Ask a diabetes expert
Other diabetes resources
Browse article topics
Daily Aspirin: Do Risks Outweigh Benefits?
Taking a daily low-dose aspirin can help prevent heart attacks or clot-related strokes in people with heart disease or a prior heart attack or stroke, but a recent report suggests that the risks of a daily aspirin regimen might outweigh the benefits in those without a history of these conditions…
Diabetes Drugs: Meglitinides
This class of drugs, also known as the nonsulfonylurea secretagogues, is relatively new compared to the sulfonylureas (chlorpropamide [brand name Diabinese], glyburide [DiaBeta, Glynase, Micronase], glipizide [Glucotrol], glipizide extended-release [Glucotrol XL], and glimepiride [Amaryl]), with the first meglitinide being approved by the U.S. Food and Drug Administration in 1997… [Glucotrol XL], and glimepiride [Amaryl]), with the first meglitinide being approved by the U.S. Food and Drug Administration in 1997. Meglitinides act in a similar manner to the sulfonylureas but with a few major differences…
Affordable Drug Combo Slashes Heart Risk by As Much As 80%
People at high risk of having a heart attack or stroke can cut their risk by as much as 80% by using a combination of three common medicines — all of them available as generics — according to a recent study published in The American Journal of Managed Care. Heart disease death rates and the risk of stroke are roughly two to four times higher in adults with diabetes than in people without diabetes…
Diabetes Drugs: DPP-4 Inhibitors
DPP-4 inhibitors, a relatively new class of drugs for Type 2 diabetes, were introduced in 2006. Sitagliptin (brand name Januvia), the first medicine in this class, was approved for the treatment of Type 2 diabetes in October 2006; in July 2009, a second DPP-4 inhibitor, saxagliptin (Onglyza), was approved…
Diabetes Drugs: Sulfonylureas
Sulfonylureas among were the first oral medicines available for the treatment of Type 2 diabetes. They were discovered by accident in France by a researcher who was working on drugs for typhoid fever. Animals that were given sulfounylureas displayed unusual behaviors and were found to have hypoglycemia (low blood glucose). It was quickly recognized that these drugs could be used for the treatment of diabetes…
Diabetes Drugs: Alpha-Glucosidase Inhibitors
Alpha-glucosidase inhibitors, a class of drugs also known as “starch blockers,” function by slowing the absorption of certain carbohydrates in the gastrointestinal tract. Two drugs in this class — acarbose (brand name Precose) and miglitol (Glyset) — are approved in the United States, while two others — voglibose (Volix and others) and emiglitate — are available only outside of the United States…
Disclaimer of Medical Advice: You understand that the blog posts and comments to such blog posts (whether posted by us, our agents or bloggers, or by users) do not constitute medical advice or recommendation of any kind, and you should not rely on any information contained in such posts or comments to replace consultations with your qualified health care professionals to meet your individual needs. The opinions and other information contained in the blog posts and comments do not reflect the opinions or positions of the Site Proprietor.
